Amanote Research
Register
Sign In
Idelalisib Bolsters CLL Regimen
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2016-002
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 15, 2016
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Idelalisib Plus Anti-Cd20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Idelalisib-Induced Pneumonitis
BMJ Case Reports
Medicine
CLL
Bone Marrow Transplantation
Transplantation
Hematology
Overview of Idelalisib for Pharmacists
Journal of Pharmacy Practice and Research
Pharmacology
Pharmacy
Sasol Bolsters Expansion With Support for Job Training
C&EN Global Enterprise
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
ISRN Oncology
Gentherapie Bei Schwerer CLL
Info Onkologie
Incidental Learning of Rewarded Associations Bolsters Learning on an Associative Task.
Journal of Experimental Psychology: Learning Memory and Cognition
Linguistics
Language
Experimental
Cognitive Psychology
A Comparison of the Appraisals by the English National Institute for Health and Care Excellence (NICE) for Two Therapies for Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL): Idelalisib+Rituximab (IR) and Ibrutinib
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
